Could This Seattle Pot Stock SOAR as Legal Weed Market Expands?
Fifteen states plus the District of Columbia now permit the recreational use of cannabis and Congress is on track to decriminalize marijuana possession on the federal level. As a result, the North American cannabis market is expected to TRIPLE in size from $30 billion to $100 billion by the year 2027 – and one Seattle manufacturer is poised to cash in!
Details in Brand-New Special Report!
Liam Ratcliffe, insider at Arvinas
Liam Ratcliffe Insider Alerts

Get notified the next time Liam Ratcliffe buys or sells Arvinas stock. Enter your email address below to get our daily insider buying and selling report.

Liam Ratcliffe Insider Information

Director of Arvinas
Dr. Liam Ratcliffe M.D., Ph.D. serves as Independent Director of the Company. Dr. Ratcliffe has been Head of Access Biotechnology, a privately held group, since April 2019. From September 2008 to March 2019, Dr. Ratcliffe was a Managing Director and Member of New Leaf Venture Partners LLC, a venture capital firm. Previously, Dr. Ratcliffe was Senior Vice President and Development Head for Neuroscience, as well as Worldwide Head of Clinical Research and Development at Pfizer, a biopharmaceutical company. Dr. Ratcliffe currently serves on the board of directors of the publicly-traded company Passage Bio, Inc. and previously served on the board of directors of the publicly-traded companies Aptinyx, Inc., Array BioPharma Inc., Deciphera Pharmaceuticals, Inc., Edge Therapeutics, Inc. and Unum Therapeutics, Inc. Dr. Ratcliffe holds a Ph.D. in immunology and an M.D. from the University of Cape Town and an M.B.A. from the University of Michigan. Ratcliffe is qualified to serve on our board due to his extensive experience in the venture capital industry, his medical and scientific background and training, and his service on the boards of directors of public and private biopharmaceutical companies.

How do I contact Liam Ratcliffe?

The corporate mailing address for Dr. Ratcliffe and other Arvinas executives is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. Arvinas can also be reached via phone at (203) 535-1456 and via email at [email protected]

Has Liam Ratcliffe been buying or selling shares of Arvinas?

During the last ninety days, Liam Ratcliffe has sold $16,302,042.00 in shares of Arvinas stock. Most recently, Liam Ratcliffe sold 21,284 shares of the business's stock in a transaction on Monday, November 15th. The shares were sold at an average price of $84.87, for a transaction totalling $1,806,373.08.

Who are Arvinas' active insiders?

Arvinas' insider roster includes Sean Cassidy (CFO), John Houston (CEO), Bradley Margus (Director), Ronald Peck (Insider), Liam Ratcliffe (Director), Timothy Shannon (Director), and Ian Taylor (Insider).

Are insiders buying or selling shares of Arvinas?

In the last year, Arvinas insiders bought shares 1 times. They purchased a total of 142,857 shares worth more than $9,999,990.00. In the last year, insiders at the sold shares 28 times. They sold a total of 693,510 shares worth more than $59,784,402.31. The most recent insider tranaction occured on November, 15th when Director Liam Ratcliffe sold 21,284 shares worth more than $1,806,373.08. Insiders at Arvinas own 6.5 % of the company.

Information on this page was last updated on 11/15/2021.

Liam Ratcliffe Insider Trading History at Arvinas

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2021Sell21,284$84.87$1,806,373.08View SEC Filing Icon  
11/12/2021Sell39,869$84.94$3,386,472.86View SEC Filing Icon  
11/10/2021Sell13,358$88.20$1,178,175.60View SEC Filing Icon  
11/8/2021Sell81,054$94.45$7,655,550.30View SEC Filing Icon  
11/5/2021Sell24,923$91.30$2,275,469.90View SEC Filing Icon  
12/18/2020Buy142,857$70.00$9,999,990.00View SEC Filing Icon  
11/12/2019Buy680,000$22.00$14,960,000.00View SEC Filing Icon  
See Full Table

Liam Ratcliffe Buying and Selling Activity at Arvinas

This chart shows Liam Ratcliffe's buying and selling at Arvinas by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arvinas Company Overview

Arvinas logo
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Read More

Today's Range

Now: $75.86
Low: $74.94
High: $80.11

50 Day Range

MA: $85.30
Low: $75.86
High: $96.21

2 Week Range

Now: $75.86
Low: $23.42
High: $108.46


463,877 shs

Average Volume

364,439 shs

Market Capitalization

$4.01 billion

P/E Ratio


Dividend Yield



Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1 Stock